ALK rearrangements occur in approximately 3–5% of NSCLC patients [50–52], more common in patients with adenocarcinoma, younger patients, and never or light smokers as well as generally mutually exclusive with other identified oncogenic drivers. Here, ALK is linked to adenocarcinoma.